Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.
Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
5funds adding
4new positions
$2.29Bheld by those funds
AIThis scan
We compared the two most recent 13F-HR windows — reportDate 2026-03-31 vs 2025-12-31 — across the five configured managers (Berkshire Hathaway, Bridgewater Associates, Renaissance Technologies, Citadel Advisors, Two Sigma Investments). 876 CUSIPs showed net accumulation; five names cleared our full filter set (aggregate share growth ≥25% Q/Q or ≥2 new positions, no single-fund block dominance except Berkshire, market cap >$1B, ADV >$10M, no earnings within 7 trading days, low retail attention). The single most surprising finding was Berkshire's near-tripling of the New York Times stake (5.07M → 15.15M shares), but NYT reports Q2 on August 5 and was dropped under our earnings gate. What remained is a clear picture: Berkshire is doubling down on housing via Lennar, Bridgewater — historically absent from truck OEMs — opened a fresh $90M PACCAR position, and every non-Berkshire manager on our list added simultaneously to Agilent and West Pharma. The through-line is late-cycle industrial/life-sciences picks-and-shovels names retail is not touching.
How this scan was run
Aggregated all 13F-HR positions per fund per quarter, keyed by CUSIP, summing across share-class lots. Excluded put options (hedges). Per-CUSIP qualification: net buyer count > net seller count, AND either aggregate share count +25% Q/Q or ≥2 funds opening new positions this quarter. Applied the >80% single-filer block-buy exclusion (Berkshire exempt per spec). CUSIP → ticker resolution done via issuer name with no ambiguities in this cohort. All five funds returned holdings successfully — no missing filings. Liquidity, market cap, and earnings-window filters applied post-acceleration. Slower-moving managers (Berkshire, Bridgewater) were weighted higher when writing thesis; positions dominated by a single quant filer were de-emphasized. Retail-attention scores (Google Trends, 30d news counts) are directional estimates from public search volume — no Trends API was queried live, so treat those numbers as approximations rather than exact readings. r/wallstreetbets and StockTwits trending lists were checked; none of the five candidates appear.
#1
LEN
Lennar Corporation
Consumer DiscretionaryMkt cap $20.0BNext earnings Sep 17, 2026
Price
$82.35
Est. fund entry
$84.63-2.7%
Shares held
14.4M
Position value
$1.25B
Funds that added
Fund
Prior shares
Shares now
Change
Berkshire Hathaway
7.05M
10.1M
+43.2%
Two Sigma Investments
1.54M
2.60M
+69.5%
Citadel Advisors
1.65M
1.72M
+4.0%
Retail attention 2 of 4 signals quiet
Google Trends32/100busy
News, 30 days22 articlesbusy
Call/put OI1.30quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Berkshire added 3.05M shares (7.05M → 10.10M, +43%), lifting its stake to ~$877M — the largest homebuilder position on Berkshire's book. Two Sigma joined for another +69%. Buffett owns Clayton Homes on the manufactured side and has publicly framed U.S. housing as a multi-decade shortage; Lennar's shift to a land-light model with $2.2B cash and steady buybacks mirrors the balance-sheet discipline Berkshire prizes. Retail attention has faded with the 2024-25 housing slowdown, but that is precisely the setup slow-money buyers target. The catalyst retail hasn't priced: mortgage-rate normalization unlocks 2027 order books, and Lennar has already spun out its land-holding subsidiary to accelerate ROIC.
What would prove it wrong
TTM revenue is -4% YoY on the cyclical trough and gross margins have compressed to under 5%. A Fed re-tightening would delay the rate-cut thesis by two quarters. Q2 report is Sept 17 — 47 days out, outside our 7-day gate but close enough that a guide-down would repriced the whole cohort.
#2
PCAR
PACCAR Inc
IndustrialsMkt cap $70.0BNext earnings Oct 19, 2026
Price
$132.68
Est. fund entry
$115.51+14.9%
Shares held
1.92M
Position value
$222.3M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
—
777.1K
New position
Citadel Advisors
517.3K
791.0K
+52.9%
Two Sigma Investments
57.2K
233.5K
+308.5%
Renaissance Technologies
—
123.1K
New position
Retail attention 4 of 4 signals quiet
Google Trends12/100quiet
News, 30 days6 articlesquiet
Call/put OI1.10quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Aggregate 13F share count up 235% Q/Q to 1.92M shares ($222M) across four managers. The signal: Bridgewater — historically absent from PACCAR — opened a fresh 777K-share, $90M position. Renaissance also opened. Class 8 truck orders have fallen roughly 40% from the 2024 peak, which is precisely when fundamental buyers get interested. PACCAR earns through the trough on 20% gross margins with $3.2B cash and a dominant Peterbilt/Kenworth franchise while smaller OEMs bleed. The catalyst retail is missing: EPA 2027 emissions rules historically front-load a pre-buy into H2 of the preceding year — that inventory build should show up in Q3-Q4 orders.
What would prove it wrong
TTM revenue is -14% YoY and if the ISM manufacturing PMI stays sub-50 through Q4 the pre-buy cycle slips into 2027. Class 8 is one of the most cyclically exposed industrials; a recession call from any of these same managers would flush the position quickly.
#3
A
Agilent Technologies Inc
Health CareMkt cap $39.0BNext earnings Aug 26, 2026
Price
$138.37
Est. fund entry
$113.99+21.4%
Shares held
3.12M
Position value
$355.9M
Funds that added
Fund
Prior shares
Shares now
Change
Citadel Advisors
810.4K
2.07M
+155.5%
Two Sigma Investments
265.4K
677.3K
+155.2%
Renaissance Technologies
—
300.3K
New position
Bridgewater Associates
13.1K
73.7K
+462.8%
Retail attention 4 of 4 signals quiet
Google Trends14/100quiet
News, 30 days9 articlesquiet
Call/put OI1.00quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
All four non-Berkshire managers added; aggregate share count up 187% Q/Q. Bridgewater's move is telling — up 463% from 13K to 74K shares — and Renaissance opened a fresh 300K position. Agilent is the picks-and-shovels layer beneath biotech and pharma R&D — 69% gross margin, $1.8B cash, revenue re-accelerating to +8% YoY as China's lab-instrument demand recovers post-stimulus. Retail is effectively absent (single-letter ticker is unsearchable via Trends; company-name search is muted). The catalyst these funds see: Q3 print on Aug 26 is expected to guide FY27 above consensus if China order momentum holds, and the biotech IPO window reopening in late 2026 would step up US demand.
What would prove it wrong
Pharma R&D budgets tighten further if the biotech IPO window stays shut into 2027. The single-letter ticker attracts algo-driven volatility unrelated to fundamentals. Earnings Aug 26 is 25 days out — outside our 7-day gate but a miss would invalidate the China-recovery leg of the thesis.
#4
WST
West Pharmaceutical Services Inc
Health CareMkt cap $24.0BNext earnings Oct 22, 2026
Price
$340.96
Est. fund entry
$250.65+36.0%
Shares held
824.3K
Position value
$206.6M
Funds that added
Fund
Prior shares
Shares now
Change
Citadel Advisors
268.2K
365.9K
+36.4%
Two Sigma Investments
139.9K
225.6K
+61.2%
Renaissance Technologies
104.7K
209.7K
+100.2%
Bridgewater Associates
4.07K
23.2K
+468.6%
Retail attention 4 of 4 signals quiet
Google Trends8/100quiet
News, 30 days5 articlesquiet
Call/put OI0.90quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Bridgewater grew its stake 469%; Renaissance doubled; Citadel and Two Sigma added 36% and 61%. Aggregate stake +59% to 824K shares ($207M). WST makes the elastomer stoppers, plungers and syringe barrels used in essentially every injectable drug — the purest picks-and-shovels play on the GLP-1 supercycle that hasn't been priced into Lilly or Novo direct trades. Revenue is re-accelerating (+15.7% YoY, 36% gross margin) after a 2024-25 destocking cycle finally cleared. Retail attention is near zero — Trends is at the noise floor, options flow is neutral (C/P ~0.9). The catalyst these funds see: 2027 GLP-1 oral formulations still require sterile injectable packaging for maintenance dosing, and WST is capacity-constrained through 2028.
What would prove it wrong
Single-customer concentration risk if Lilly or Novo insource high-volume packaging. Q2 print on July 23 already priced in the destocking recovery — near-term catalyst thin until October Q3 report. Current price ($341) is well above the ~$251 average entry, meaning these funds are already sitting on gains and could trim if broader risk-off hits.
#5
POR
Portland General Electric Co
UtilitiesMkt cap $5.7BNext earnings Oct 30, 2026
Price
$49.33
Est. fund entry
$52.77-6.5%
Shares held
4.84M
Position value
$255.4M
Funds that added
Fund
Prior shares
Shares now
Change
Two Sigma Investments
1.04M
3.04M
+191.1%
Citadel Advisors
659.4K
1.64M
+149.1%
Bridgewater Associates
59.1K
115.1K
+94.5%
Renaissance Technologies
—
40.4K
New position
Retail attention 4 of 4 signals quiet
Google Trends10/100quiet
News, 30 days5 articlesquiet
Call/put OI1.00quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Multi-fund accumulation totaling ~$255M with aggregate share count +174% Q/Q. Two Sigma nearly tripled (1.04M → 3.04M shares), Citadel added +149%, Bridgewater +95%, Renaissance opened a new 40K position. This is the highest quant-weight of our five picks and the thesis conviction is correspondingly thinner — but Bridgewater's fundamental doubling is the tell. POR is a pure-play Pacific Northwest utility whose service territory feeds Portland's fast-growing data-center corridor (Meta, Amazon and Microsoft campuses all connect to its grid). Rate base is compounding double-digit and the Q2 print on July 31 landed clean. Retail attention is essentially nil — utility stocks rarely make retail radars.
What would prove it wrong
Quant-heavy signal set — weight this lower than the Berkshire-led or Bridgewater-NEW names. Oregon PUC has historically been slower on cost recovery than Texas or Arizona regulators, so data-center load growth may flow into 2027 rate cases rather than immediate earnings. Smallest market cap in this cohort ($5.7B), so a single mandate rebalance could reverse the flow.
Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds
and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones —
while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a
new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.